A Phase 2 interventional study of Kava and Placebo in Smoking, sponsored by University of Florida. Terminated at 1 site in United States. Open to participants aged 21 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by University of Florida · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 899 studies in Smoking with a site in United States — 90 open to participants now, 110 under way, 4 of them phase 3. Smoking · United States.
Among the 899 studies in Smoking with a site in United States, this one is the 698th largest by enrollment of the 785 interventional ones that give a count, is one of 45 that started in 2022, is one of 75 in phase 2, and was the 737th registered.
1,516 studies on the registry are indexed under Smoking; 196 are open to participants now.
Browse Smoking studies →90 of the 899 studies in Smoking with a site in United States are open now. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 18+
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 18+
Georgia State University · Sites in United States
Ages 21+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 145 Smoking studies recruiting now, 76 (52%) set no upper age limit and 51 (35%) stop at 75 or younger; 3 take children under 18; 69 take healthy volunteers.
This study: 21 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
899 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 112 · Phase 3 64 · Phase 4 67
First in 1993; this study’s year is marked. 45 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 116 across 1,167 interventional studies indexed under Smoking.
Median enrollment 109 across the 785 interventional studies, 131 across the 108 observational. Of the 742 that completed or were terminated, 293 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
101 of 899 have an industry lead sponsor. The 10 most frequent:
University of Florida is the lead sponsor of 1,290 studies on the registry; 202 are open to participants now.
Of its 181 completed or terminated interventional studies of FDA-regulated products, 143 (79%) have results posted.
University of Florida has 5 studies filed under Smoking — fewer than ten, so there is no comparison to draw.
57 of the studies in Smoking with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07119489Wake Forest University Health SciencesA Novel Dialectical Behavior Therapy Brief Group Intervention for Cigarette Smoking by Patients With Cancer: An Open Clinical Trial | 2026-11 |
| NCT06945120Dana-Farber Cancer InstituteACT Lung Health Intervention: Phase Two | 2026-11-30 |
| NCT04968249University of MichiganMichigan Early Disease Progression Cohort | 2026-12 |
| NCT07710820RAI Services CompanyA Multi-Site Study to Assess the Effect of Availability of a Heated Tobacco Product on Smoking Abstinence Among Current Primary Cigarette Smokers | 2026-12 |
| NCT06837220University of ChicagoImplementation of Tobacco Cessation Programming at Community Behavioral Health Sites | 2026-12 |
Add all 57 to your calendar (.ics) → With an account.
Among the 899 studies in Smoking with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Tobacco use is the leading cause of many preventable diseases, particularly lung cancer. Based on the national cancer data in 2020, Florida has the highest lung cancer incidence (18,150 cases) with the most deaths (10,580 deaths) among all the states in the United States. Unfortunately, around 16% of adults in Florida continue to smoke cigarettes due to its addictive nature and the limited success of current cessation strategies. Therefore, there is an unmet and urgent need for novel interventions to improve the success of tobacco cessation. If such an intervention can reduce tobacco-associated lung carcinogenesis, that will be more desirable. The ultimate goal of this study is to develop a safe and effective kava-based intervention to enable tobacco cessation and reduce lung cancer risk, which will improve the health of Floridians.
This study will evaluate the compliance with a daily kava regimen among active smokers who have no intention to quit smoking. This study will also investigate whether kava use can reduce tobacco use and dependence, as well as tobacco-associated lung carcinogenesis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Kava
Drug: Placebo
Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 28 days.
Participants on this arm will take one placebo capsule orally three times daily for 28 days.
Urinary Total Nicotine Equivalents
Measure urinary total nicotine equivalents (TNE). TNE is the sum of nicotine and its metabolites in a participant's urine. TNE was measured at baseline (on Day 1 of treatment), after 1 and 2 weeks on treatment, at the end of treatment, at 4 weeks after end of treatment and at 8 weeks after end of treatment.
Time frame: at baseline (on Day 1 of treatment), after 1 and 2 weeks on treatment, at the end of treatment, at 4 weeks after end of treatment and at 8 weeks after end of treatment.
Reinforcing Effects of Smoking
Determine if participants experience reinforcing effects of smoking using the Modified Cigarette Evaluation Questionnaire. Subjects respond with a whole number numerical value from 1 to 7 for each item. The item responses are used to determine 5 scores: smoking satisfaction, psychological reward, aversion, enjoyment of respiratory tract sensations and craving reduction. Each score is either the response to a single item (for the enjoyment of respiratory tract sensations and craving reduction scores) or is calculated as the mean of multiple individual item responses (for the smoking satisfaction, psychological reward, and aversion scores). Possible values for each score range from a minimum of 1 and a maximum of 7. A higher value is worse for the smoking satisfaction, psychological reward and craving reduction scores. A lower value is worse for the aversion score. A higher score for the respiratory tract sensations score means greater enjoyment of respiratory tract sensations.
Time frame: At baseline (Day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment (28 days after starting treatment)
Participant Reported Number of Cigarettes Smoked Weekly
Determine the participant reported number of cigarettes smoked weekly. The number of cigarettes smoked was measured by having participants document how many cigarettes they smoked in the past week on a calendar. Participants completed this at baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment.
Time frame: At baseline (day 1) of treatment, at 1 week and 2 weeks after beginning treatment, and at the end of treatment (28 days after beginning treatment)
Participant Urge to Smoke
Measure participant urge to smoke using the Brief Questionnaire on Smoking Urges (QSU-Brief). The QSU-Brief is a 10-item scale, assessing the features of craving, including the anticipation of relief of nicotine withdrawal, anticipation of positive outcomes of smoking, desire to smoke, and intention to smoke. Participants respond with a score from 1 (best) to 7 (worst) for each item. Possible total scores range from 10 to 70, with a higher score meaning a greater urge to smoke. Participants completed the QSU-Brief at baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment.
Time frame: At baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment (28 days after beginning treatment)
Nicotine Dependency
Measure participant nicotine dependency using the Fagerström Test for Nicotine Dependence (FTND). The FTND is a 6-item scale measuring the level of nicotine dependency or addiction. It assesses how soon tobacco use begins each day, which cigarettes during the day a person could do without, how smokers cope in places where they cannot smoke, and how frequently and how deeply they smoke. Responses for each item are given either 0 points or 1 point for 4 items and 0-3 points for 2 items, with more points meaning a greater nicotine dependency. Possible total scores range from 0 to 10 points, with a higher score meaning a greater nicotine dependency. Participants completed the FTND at baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment.
Time frame: At baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment (28 days after beginning treatment)
Perceived Stress
Measure participant perceived stress using the Perceived Stress Scale (PSS). The PSS is a 10-item scale measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. The scale also includes a number of direct queries about current levels of experienced stress. Participants respond to each item with a score of 0 ("never") to 4 ("very often"). A higher score is worse for the 6 items assessing negative outcomes, such as how often participants felt nervous and stressed and a lower score is worse for the 4 items assessing positive outcomes, such as how often participants felt on top of things. Possible total scores range from 0 to 40, with a higher score meaning higher perceived stress. Participants completed the PSS at baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment.
Time frame: At baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment (28 days after beginning treatment)
Severity of Insomnia
Measure severity of participant insomnia using the Insomnia Severity Scale. The Insomnia Severity Scale is a 7-item self-report questionnaire assessing the nature, severity, and impact of insomnia. Participants respond to each item with a score of 0 (best) to 4 (worst). Possible total scores range from 0 to 28, with a higher score meaning more severe insomnia. Participants completed the Insomnia Severity Scale at baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment.
Time frame: At baseline (day 1) of treatment, at 1 week and 2 weeks after beginning treatment, and at the end of treatment (28 days after beginning treatment)
Compliance Score Percentage
Evaluate subject compliance with the kava intervention, as measured by the compliance score percentage. The compliance score percentage was calculated by dividing the total number of kava or placebo capsules actually consumed across all visits by the total number of kava or placebo capsules expected to be consumed across all visits and multiplying the result by 100.
Time frame: At end of treatment (28 days after starting treatment)
Participant Compliance Status
Determine participant compliance status, defined as whether the number of kava or placebo capsules expected to be returned matched the number of kava or placebo capsules actually returned by a participant across all visits, with "Yes" indicating a match and "No" indicating a mismatch.
Time frame: At end of treatment (28 days after starting treatment)
| Milestone | Kava Intervention | Placebo Control |
|---|---|---|
| Started | 9 | 10 |
| Completed | 9 | 10 |
| Not completed | 0 | 0 |
Measure urinary total nicotine equivalents (TNE). TNE is the sum of nicotine and its metabolites in a participant's urine. TNE was measured at baseline (on Day 1 of treatment), after 1 and 2 weeks on treatment, at the end of treatment, at 4 weeks after end of treatment and at 8 weeks after end of treatment.
| nmol/mg creatinine | Kava | Placebo |
|---|---|---|
| Baseline | 68.72 (57.49 to 79.94) | 64.53 (48.75 to 80.32) |
| After 1 week on treatment | 77.84 (59.20 to 96.48) | 63.59 (48.51 to 78.68) |
| After 2 weeks on treatment | 95.45 (67.48 to 123.41) | 67.98 (49.27 to 86.68) |
| End of treatment | 74.28 (57.10 to 91.47) | 59.43 (43.16 to 75.70) |
| 4 weeks after end of treatment | 76.68 (57.25 to 96.11) | 72.22 (50.58 to 93.85) |
| 8 weeks after end of treatment | 95.21 (72.21 to 118.22) | 70.28 (53.30 to 87.26) |
Determine if participants experience reinforcing effects of smoking using the Modified Cigarette Evaluation Questionnaire. Subjects respond with a whole number numerical value from 1 to 7 for each item. The item responses are used to determine 5 scores: smoking satisfaction, psychological reward, aversion, enjoyment of respiratory tract sensations and craving reduction. Each score is either the response to a single item (for the enjoyment of respiratory tract sensations and craving reduction scores) or is calculated as the mean of multiple individual item responses (for the smoking satisfaction, psychological reward, and aversion scores). Possible values for each score range from a minimum of 1 and a maximum of 7. A higher value is worse for the smoking satisfaction, psychological reward and craving reduction scores. A lower value is worse for the aversion score. A higher score for the respiratory tract sensations score means greater enjoyment of respiratory tract sensations.
| score | Kava Arm | Placebo Arm |
|---|---|---|
| Smoking Satisfaction Score (Baseline) | 3.44 ± 1.26 | 3.95 ± 1.38 |
| Psychological Reward Score (Baseline) | 3.49 ± 1.01 | 4.08 ± 1.41 |
| Aversion Score (Baseline) | 1.33 ± 0.83 | 2.10 ± 0.91 |
| Enjoyment of Respiratory Tract Sensations Score (Baseline) | 2.78 ± 1.39 | 1.60 ± 0.52 |
| Craving Reduction Score (Baseline) | 4.22 ± 1.72 | 4.00 ± 1.94 |
| Smoking Satisfaction Score (1 week after beginning treatment) | 2.93 ± 1.37 | 3.47 ± 0.98 |
| Psychological Reward Score (1 week after beginning treatment) | 2.84 ± 0.66 | 3.48 ± 1.38 |
| Aversion Score (1 week after beginning treatment) | 1.78 ± 1.09 | 2.15 ± 1.25 |
| Enjoyment of Respiratory Tract Sensations Score (1 week after beginning treatment) | 2.44 ± 1.74 | 1.80 ± 0.92 |
| Craving Reduction Score (1 week after beginning treatment) | 4.11 ± 1.62 | 4.40 ± 1.65 |
| Smoking Satisfaction Score (2 weeks after beginning treatment) | 2.59 ± 1.42 | 3.37 ± 1.11 |
| Psychological Reward Score (2 weeks after beginning treatment) | 2.80 ± 1.45 | 2.93 ± 1.61 |
| Aversion Score (2 weeks after beginning treatment) | 2.06 ± 1.94 | 1.94 ± 0.88 |
| Enjoyment of Respiratory Tract Sensations Score (2 weeks after beginning treatment) | 2.63 ± 1.92 | 1.78 ± 0.83 |
| Craving Reduction Score (2 weeks after beginning treatment) | 3.44 ± 2.24 | 3.67 ± 1.80 |
| Smoking Satisfaction Score (End of treatment) | 2.42 ± 1.29 | 2.96 ± 1.36 |
| Psychological Reward Score (End of treatment) | 2.80 ± 1.40 | 2.62 ± 1.36 |
| Aversion Score (End of treatment) | 1.50 ± 1.22 | 1.78 ± 0.83 |
| Enjoyment of Respiratory Tract Sensations Score (End of treatment) | 2.13 ± 1.13 | 1.89 ± 1.05 |
| Craving Reduction Score (End of treatment) | 3.75 ± 2.12 | 3.56 ± 2.30 |
Determine the participant reported number of cigarettes smoked weekly. The number of cigarettes smoked was measured by having participants document how many cigarettes they smoked in the past week on a calendar. Participants completed this at baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment.
| cigarettes smoked weekly | Kava Arm | Placebo Arm |
|---|---|---|
| Baseline | 18.74 ± 8.60 | 18.99 ± 9.97 |
| 1 week after beginning treatment | 19.06 ± 13.45 | 15.01 ± 8.68 |
| 2 weeks after beginning treatment | 18.75 ± 15.64 | 11.14 ± 7.90 |
| End of treatment | 18.02 ± 17.25 | 10.83 ± 8.21 |
Measure participant urge to smoke using the Brief Questionnaire on Smoking Urges (QSU-Brief). The QSU-Brief is a 10-item scale, assessing the features of craving, including the anticipation of relief of nicotine withdrawal, anticipation of positive outcomes of smoking, desire to smoke, and intention to smoke. Participants respond with a score from 1 (best) to 7 (worst) for each item. Possible total scores range from 10 to 70, with a higher score meaning a greater urge to smoke. Participants completed the QSU-Brief at baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment.
| score on a scale | Kava Arm | Placebo Arm |
|---|---|---|
| Total score - Baseline | 34.89 ± 15.95 | 31.30 ± 19.03 |
| Total score - 1 week after beginning treatment | 27.56 ± 12.73 | 17.10 ± 6.76 |
| Total score - 2 weeks after beginning treatment | 25.67 ± 13.64 | 18.78 ± 8.58 |
| Total score - End of treatment | 22.13 ± 13.23 | 14.67 ± 3.24 |
Measure participant nicotine dependency using the Fagerström Test for Nicotine Dependence (FTND). The FTND is a 6-item scale measuring the level of nicotine dependency or addiction. It assesses how soon tobacco use begins each day, which cigarettes during the day a person could do without, how smokers cope in places where they cannot smoke, and how frequently and how deeply they smoke. Responses for each item are given either 0 points or 1 point for 4 items and 0-3 points for 2 items, with more points meaning a greater nicotine dependency. Possible total scores range from 0 to 10 points, with a higher score meaning a greater nicotine dependency. Participants completed the FTND at baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment.
| score on a scale | Kava Arm | Placebo Arm |
|---|---|---|
| Total score - Baseline | 6.00 ± 1.87 | 5.80 ± 2.15 |
| Total score - 1 week after beginning treatment | 5.33 ± 2.00 | 4.90 ± 1.91 |
| Total score - 2 weeks after beginning treatment | 5.11 ± 3.06 | 4.11 ± 1.62 |
| Total score - End of treatment | 4.50 ± 3.07 | 4.56 ± 1.67 |
Measure participant perceived stress using the Perceived Stress Scale (PSS). The PSS is a 10-item scale measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. The scale also includes a number of direct queries about current levels of experienced stress. Participants respond to each item with a score of 0 ("never") to 4 ("very often"). A higher score is worse for the 6 items assessing negative outcomes, such as how often participants felt nervous and stressed and a lower score is worse for the 4 items assessing positive outcomes, such as how often participants felt on top of things. Possible total scores range from 0 to 40, with a higher score meaning higher perceived stress. Participants completed the PSS at baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment.
| score on a scale | Kava Arm | Placebo Arm |
|---|---|---|
| Total score - Baseline | 20.22 ± 7.61 | 18.40 ± 11.65 |
| Total score - 1 week after beginning treatment | 16.67 ± 7.16 | 16.50 ± 11.28 |
| Total score - 2 weeks after beginning treatment | 17.78 ± 7.61 | 14.44 ± 10.81 |
| Total score - End of treatment | 16.63 ± 7.56 | 15.11 ± 10.87 |
Measure severity of participant insomnia using the Insomnia Severity Scale. The Insomnia Severity Scale is a 7-item self-report questionnaire assessing the nature, severity, and impact of insomnia. Participants respond to each item with a score of 0 (best) to 4 (worst). Possible total scores range from 0 to 28, with a higher score meaning more severe insomnia. Participants completed the Insomnia Severity Scale at baseline (day 1 of treatment), at 1 week and 2 weeks after beginning treatment, and at the end of treatment.
| score on a scale | Kava Arm | Placebo Arm |
|---|---|---|
| Total score - Baseline | 12.00 ± 7.28 | 12.80 ± 6.73 |
| Total score - 1 week after beginning treatment | 7.33 ± 5.72 | 7.90 ± 7.06 |
| Total score - 2 weeks after beginning treatment | 8.33 ± 6.93 | 7.44 ± 6.52 |
| Total score - End of treatment | 7.13 ± 7.16 | 7.56 ± 8.23 |
Evaluate subject compliance with the kava intervention, as measured by the compliance score percentage. The compliance score percentage was calculated by dividing the total number of kava or placebo capsules actually consumed across all visits by the total number of kava or placebo capsules expected to be consumed across all visits and multiplying the result by 100.
| percentage | Kava Arm | Placebo Arm |
|---|---|---|
| Compliance Score Percentage | 97.6 ± 2.8 | 98.3 ± 3.5 |
Determine participant compliance status, defined as whether the number of kava or placebo capsules expected to be returned matched the number of kava or placebo capsules actually returned by a participant across all visits, with "Yes" indicating a match and "No" indicating a mismatch.
| Participants | Kava Arm | Placebo Arm |
|---|---|---|
| Yes | 4 | 7 |
| No | 5 | 3 |
Collected over Adverse events were collected from the date on which the first kava or placebo capsules were dispensed to the participant until the Week 12 follow-up visit. Adverse event data were collected for a maximum of 12 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Kava Intervention | 0/9 (0%) | 0/9 (0%) | 1/9 (11.1%) |
| Placebo Control | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Event | Kava Intervention | Placebo Control |
|---|---|---|
| Aspartate aminotransferase increasedInvestigations | 0/9 | 2/10 |
| Alanine aminotransferase increasedInvestigations | 0/9 | 2/10 |
| HeadacheNervous system disorders | 0/9 | 2/10 |
| Creatinine increasedInvestigations | 0/9 | 2/10 |
| HypercalcemiaMetabolism and nutrition disorders | 0/9 | 2/10 |
| DizzinessNervous system disorders | 1/9 | 0/10 |
| Back painMusculoskeletal and connective tissue disorders | 0/9 | 1/10 |
| AnemiaBlood and lymphatic system disorders | 0/9 | 1/10 |
| HyponatremiaMetabolism and nutrition disorders | 0/9 | 1/10 |
| Chronic kidney diseaseRenal and urinary disorders | 0/9 | 1/10 |
| Age, Categorical(Participants) | Kava Intervention | Placebo Control | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 9 | 17 |
| >=65 years | 1 | 1 | 2 |
| Age, Continuous(years) | Kava Intervention | Placebo Control | Total |
|---|---|---|---|
| Mean | 56.44 (49 to 68) | 57.9 (45 to 70) | 57.21 (45 to 70) |
| Sex: Female, Male(Participants) | Kava Intervention | Placebo Control | Total |
|---|---|---|---|
| Female | 7 | 9 | 16 |
| Male | 2 | 1 | 3 |
| Race (NIH/OMB)(Participants) | Kava Intervention | Placebo Control | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 5 | 5 |
| White | 9 | 5 | 14 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Kava Intervention | Placebo Control | Total |
|---|---|---|---|
| United States | 9 | 10 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2022 to primary completion in Jun 2025, 36 months.
Results were first posted in Sep 2026, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Piper methysticum root